| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (NCT05153226) | DKMS gemeinnützige GmbH | 2022-03-02 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (NCT04730258) | Treadwell Therapeutics, Inc | 2021-04-16 |
| Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients (NCT04806906) | University of Florence | 2021-03-24 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML (NCT04372433) | Immune-Onc Therapeutics | 2020-09-14 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML (NCT04139434) | Newave Pharmaceutical Inc | 2020-07-06 |
| Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML (NCT07318662) | Guangdong Provincial People's Hospital | 2020-01-01 |
| Ascorbic Acid Levels in MDS, AML, and CMML Patients (NCT03526666) | Van Andel Research Institute | 2017-11-01 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations (NCT02418000) | Spirita Oncology, LLC | 2015-04-10 |
| A Study of Eltrombopag in Patients With CMML and Thrombocytopenia (NCT02323178) | Groupe Francophone des Myelodysplasies | 2014-08-07 |
| Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies (NCT02193958) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2014-07-01 |
| SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (NCT01261312) | Astex Pharmaceuticals, Inc. | 2011-01-04 |
| Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML (NCT06267898) | European Society for Blood and Marrow Transplantation | 2009-11-01 |